Clinical Trial

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Study acronym: LEAP
Recruiting
View on ClinicalTrials.gov →
Summary
The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-21; most recent amendment 2025-05-21.
Trial Details
NCT Number NCT06193928
Lead Sponsor Mirum Pharmaceuticals, Inc.
Conditions Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Enrollment 70 participants
Start Date 2023-09-21
Primary Completion 2028-09-20 (estimated)
Study Completion 2030-09-20 (estimated)
Updated on ClinicalTrials.gov 2025-05-25